The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01335230 |
Recruitment Status
:
Completed
First Posted
: April 14, 2011
Results First Posted
: August 5, 2014
Last Update Posted
: September 11, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
HIV Hepatitis C, Chronic HCV Coinfection |
Objective 1: Characterization of the Gut Associated Lymphocytes (GALT) in HIV, HCV and coinfected patients regarding the role of Th17 and cytokine profiles.
Hypothesis 1a: HIV and HCV/HIV coinfection is associated with changes in Th17 numbers and functions in GALT.
Hypothesis 1b: HIV and HCV/HIV coinfection is associated with changes in cytokine profiles in intestinal mucosa.
Objective 2: Identify the relationship between changes in Gut Associated Lymphocytes (GALT) in HIV, HCV and coinfected patients and markers of microbial translocation.
Hypothesis 2a: Changes in GALT are associated with increase in microbial translocation in HIV, HCV and coinfected patients.
Study Type : | Observational |
Actual Enrollment : | 40 participants |
Observational Model: | Case Control |
Time Perspective: | Cross-Sectional |
Official Title: | Exploring the Role of Gut-associated TH17 in Microbial Translocation in HIV and HCV/HIV Co-infected Patients |
Study Start Date : | April 2011 |
Actual Primary Completion Date : | January 2013 |
Actual Study Completion Date : | January 2013 |

Group/Cohort |
---|
10 HIV mono-infected subjects
10 subjects infected with HIV only
|
10 HCV mono-infected subjects
10 subjects infected with HCV only
|
10 HIV/HCV co-infected subjects
10 subjects infected with both HIV and HCV
|
10 control subjects
10 subjects without HIV, HCV, or both
|
- Exploring the Role of Gut-associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients. [ Time Frame: One year ]We measure gene transcription of the colon tissues (relative expression fold changes of gene transcription compared to control). No preselected criteria were used to assess the participants. Data were analyzed and compared among each group. Relative expression levels of LEAP-2 (Liver expressed anti-microbial peptide-2) in the four groups were shown in the table below. Detailed of other genes had been published in Shata MT, et al, J. Clin Pathology 2013, Nov 66(11):967-75. PMID 23940131, and Abdel-Hameed et al, J. Acquir Immune Defic Syndr. 2013 Jul 10 PMID: 23846566
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- are at least age 18, but not older than 70 years old
- have HIV, HCV or both
- do not have HIV, HCV or both, and are having a screening colonoscopy or flexible sigmoidoscopy for abdominal pain or colon cancer screening (control subject)
Exclusion Criteria:
- have a history of inflammatory bowel diseases (IBD) or suspected IBD
- have a history of autoimmune diseases including rheumatoid arthritis
- are taking systemic immunomodulators
- are pregnant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01335230
United States, Ohio | |
University of Cincinnati | |
Cincinnati, Ohio, United States, 45267 |
Principal Investigator: | M. Tarek Shata, MD, PhD | University of Cincinnati |
Publications of Results:
Responsible Party: | Mohamed Tarek Shata, Principal Investigator, University of Cincinnati |
ClinicalTrials.gov Identifier: | NCT01335230 History of Changes |
Other Study ID Numbers: |
UC 10110905 |
First Posted: | April 14, 2011 Key Record Dates |
Results First Posted: | August 5, 2014 |
Last Update Posted: | September 11, 2015 |
Last Verified: | August 2015 |
Keywords provided by Mohamed Tarek Shata, University of Cincinnati:
HIV HCV Hepatitis C HIV and Hepatitis C coinfection HIV/HCV |
Additional relevant MeSH terms:
Hepatitis Hepatitis C Hepatitis C, Chronic Coinfection Liver Diseases Digestive System Diseases Hepatitis, Viral, Human |
Virus Diseases Flaviviridae Infections RNA Virus Infections Hepatitis, Chronic Infection Parasitic Diseases |